Eli Lilly and Company (NYSE:LLY) Stock Price Down 1.4% – Here’s What Happened

Eli Lilly and Company (NYSE:LLY) shares fell 1.4% on Wednesday. The company traded as low as $1,145.98 and last traded at $1,153.6920. 2,145,076 shares traded hands during mid-day trading, a decline of 29% from the average session volume of 3,016,490 shares. The stock had previously closed at $1,170.14.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approves once-weekly insulin: The FDA approved Onswik, Lilly’s once-weekly basal insulin for adults with type 2 diabetes. The treatment could reduce injections by more than 300 annually versus daily basal insulin and expands Lilly’s diabetes portfolio beyond its GLP-1 products. The approval was supported by the Phase 3 QWINT program, which involved more than 3,400 patients. Reuters Onswik FDA approval
• Positive Sentiment: Strategic drug-discovery deal: Lilly agreed to a research collaboration and licensing pact with China’s InnoCare worth up to approximately $3.35 billion, including a reported $100 million upfront payment. The agreement covers as many as five undisclosed targets and could strengthen Lilly’s future pipeline in oncology and autoimmune disease. Reuters InnoCare collaboration
• Positive Sentiment: Capacity expansion supports obesity-drug growth: Lilly broke ground on a $6.5 billion Houston manufacturing facility intended to support production, including ingredients for its planned oral GLP-1 rollout. The investment signals confidence in sustained demand for Lilly’s diabetes and weight-loss medicines. Houston manufacturing plant
• Neutral Sentiment: Long-term optimism remains high: Investor Ken Langone said LLY could reach $2,000 in three to four years, reflecting confidence in Lilly’s obesity-drug franchise. However, this is an individual opinion rather than a formal analyst estimate. TheStreet Ken Langone comments
• Negative Sentiment: Competition and valuation remain risks: Novo Nordisk is attempting to regain obesity-market momentum, while Viking Therapeutics reported encouraging maintenance data for VK2735. With LLY trading at a premium earnings multiple near 39, investors may be taking profits or demanding stronger evidence that Lilly can maintain its rapid growth.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on LLY shares. Cantor Fitzgerald lifted their price target on shares of Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Weiss Ratings raised Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, August 26th. Wall Street Zen lowered Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Sunday, August 23rd. Citigroup upped their price target on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Finally, Guggenheim increased their price target on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a research note on Friday, September 18th. One analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $1,308.39.

Eli Lilly and Company Stock Performance

The company has a 50-day moving average of $1,176.99 and a 200 day moving average of $1,082.06. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The firm has a market capitalization of $1.12 trillion, a PE ratio of 39.76, a PEG ratio of 1.44 and a beta of 0.50.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same period in the previous year, the firm posted $6.31 EPS. The firm’s revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities research analysts predict that Eli Lilly and Company will post 36.54 EPS for the current year.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock worth $15,958,170 over the last ninety days. Insiders own 0.14% of the company’s stock.

Institutional Trading of Eli Lilly and Company

Several hedge funds have recently added to or reduced their stakes in the business. QRG Capital Management Inc. lifted its stake in shares of Eli Lilly and Company by 9.6% in the 2nd quarter. QRG Capital Management Inc. now owns 146,305 shares of the company’s stock valued at $175,483,000 after acquiring an additional 12,755 shares during the last quarter. Envestnet Portfolio Solutions Inc. boosted its holdings in Eli Lilly and Company by 7.7% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 41,689 shares of the company’s stock valued at $49,991,000 after acquiring an additional 2,976 shares during the period. State Street Corp grew its position in Eli Lilly and Company by 1.7% during the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company’s stock worth $43,438,262,000 after acquiring an additional 605,752 shares during the last quarter. Silicon Valley Capital Partners grew its position in Eli Lilly and Company by 3.7% during the 2nd quarter. Silicon Valley Capital Partners now owns 13,489 shares of the company’s stock worth $16,179,000 after acquiring an additional 480 shares during the last quarter. Finally, Security National Bank of Sioux City Iowa IA purchased a new position in Eli Lilly and Company in the 2nd quarter worth approximately $120,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company’s products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer’s disease.